NCT07947329
Treatments for Menstrual-Related Epilepsy
StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Treatment efficacy in reducing perimenstrual seizure frequency
Timeframe: at the end of month 3
Secondary (1)
Treatment withdrawal rate
Arms and interventions
ClobazamActive comparator
One clobazam 10 mg tablet every 12 hours for 3 months on days -5 to +5 of the menstrual cycle.
AcetazolamideActive comparator
One acetazolamide 250 mg tablet every 12 hours for 3 months on days -5 to +5 of the menstrual cycle.
A 25% increase in the dose of the baseline antiseizure medicationActive comparator
A 25% increase in the dose of the baseline antiseizure medication for 3 months on days -5 to +5 of the menstrual cycle. If the patient is on polytherapy, the dose of one of the administered antiseizure medications that does not exceed the therapeutic range with a 25% increase will be escalated.
Drugs: Clobazam 10 MG Oral Tablet, Acetazolamide 250Mg Tab, Antiepileptic
Sites
1 site in 1 country
- Mazandaran University of Medical SciencesSari, Mazandaran, Iran